首页>
外军国防科技报告
>Incidence of Chemotherapy-Induced Amenorrhea in Premenopausal Patients with Breast Cancer Following Adjuvant Chemotherapy with Anthracycline and Taxane
【2h】
Incidence of Chemotherapy-Induced Amenorrhea in Premenopausal Patients with Breast Cancer Following Adjuvant Chemotherapy with Anthracycline and Taxane
Breast cancer (BC) is the second incidence and the fifth leading cause to cancer death in the worldwide. In developing countries, the number of BC cases is still increased annually accompanied with the changes of lifestyle and screening programs. Nevertheless, the majority of BC patients are diagnosed as non-curative stage. Thereby, systemic therapy always plays an important role in BC treatment strategies. Among chemotherapy regimens, the combination of anthracyclin and taxane as an adjuvant treatment has been proven the efficacy and safety in terms of prolonging survival. In this study, we evaluated t,he incidence of chemotherapy-induced amenorrhea in breast cancer patients who were treated with adjuvant anthracycline and taxane-based chemotherapy.,
展开▼
